Benign Prostatic Hyperplasia Diagnosis

Introduction to BPH Diagnosis

• The American Urological Association and European Association of Urology suggest that PSA is not a specific marker for BPH, but rather reflects prostate volume and can be affected by multiple factors, and BPH can occur with normal PSA levels 1, 2

Diagnostic Evaluation

• The American Urological Association recommends digital rectal examination (DRE) to assess prostate size, and urinalysis to rule out other causes of lower urinary tract symptoms (LUTS) 1
• DRE tends to underestimate the true prostate size; if the prostate feels large by DRE, it usually is enlarged by ultrasound 1

PSA Interpretation

• PSA velocity may provide additional information, especially in men with PSA values in the normal range, according to the Mayo Clinic and American Urological Association 3, 1
• Serial PSA measurements, such as those taken over 18 months, can help inform the diagnosis and management of BPH, and a single PSA measurement should not be relied upon 3, 1
• At least 3 PSA measurements, preferably throughout at least 18 months, are recommended for interpretation of PSA velocity 3
• PSA levels above 10.0 ng/mL are strongly associated with aggressive disease, with a high level suggesting advanced disease, possibly with metastatic spread, according to the National Comprehensive Cancer Network guidelines 4
• The risk of prostate cancer increases with PSA level:
• PSA velocity has limited utility in patients with PSA > 10 ng/mL, but for patients with PSA < 4 ng/mL, a velocity > 0.35 ng/mL/year is suspicious for cancer, while for patients with PSA 4-10 ng/mL, a velocity > 0.75 ng/mL/year is suspicious for cancer, as recommended by the National Comprehensive Cancer Network 4

Factors Affecting PSA Levels

• Biological variability can cause PSA levels to fluctuate due to factors unrelated to cancer 4
• Prostatitis can cause temporary PSA elevations; consider antibiotic therapy and repeat measurements, as recommended by the National Comprehensive Cancer Network 4
• Finasteride and dutasteride can lower PSA values by approximately 50%, according to the National Comprehensive Cancer Network and other studies 4, 3
• Recent ejaculation can temporarily elevate PSA; abstain from ejaculation for 48 hours before testing, as recommended by the National Comprehensive Cancer Network 4
• PSA measurements can vary by 20-25% depending on standardization methods, and the American Urological Association recommends using the same assay for longitudinal monitoring, as PSA assays are not interchangeable 5

Biopsy and Screening

• A single elevated PSA should not prompt immediate biopsy, and abnormal findings on digital rectal examination should be considered when evaluating the need for biopsy, as recommended by the European Society for Medical Oncology 6
• Transrectal ultrasound-guided prostate biopsy under antibiotic cover and local anesthesia is recommended when biopsy is indicated, with a minimum of 10-12 cores obtained, as recommended by the European Society for Medical Oncology 6
• Consider multi-parametric MRI before repeat biopsy if previous biopsies were negative, as recommended by the European Society for Medical Oncology 6
• Baseline PSA testing is recommended for men aged 45-50, with annual to biannual follow-up if PSA ≥1.0 ng/mL and retesting at age 50 if PSA <1.0 ng/mL, according to the American Urological Association 7
• Routine PSA testing is recommended for men aged 50-70, with follow-up based on age-specific cut-offs for biopsy decisions, as recommended by the National Comprehensive Cancer Network 7
• Individualized screening is recommended for men aged 70-75, based on PSA history, with consideration of discontinuing screening if PSA consistently <3.0 ng/mL, according to the American Academy of Family Physicians and the National Comprehensive Cancer Network 8, 9, 10
• Limited benefit from screening is expected for men aged >75, with consideration of continuing only in very select patients with excellent health status, according to the BMJ guidelines and the American Academy of Family Physicians 8, 11, 9

Treatment Considerations

• The Gleason score is used to determine biological aggressiveness, with Gleason 6 indicating lower biological aggressiveness, Gleason 7 indicating intermediate biological aggressiveness, and Gleason ≥8 indicating biologically aggressive tumor, as defined by the World Health Organization and the National Comprehensive Cancer Network 5, 10
• Treatment decisions should consider the patient's overall health and life expectancy, and the patient's comorbidities should be taken into account when determining the best course of treatment, as recommended by the American Academy of Family Physicians and the National Comprehensive Cancer Network 9, 10
• Life expectancy <10 years may favor less aggressive approaches, according to the BMJ guidelines and the American Academy of Family Physicians 11, 9